Arvinas just reported Q1 earnings — and the stock fell 5% anyway, now down nearly 10% on the week to $9.57.
The disconnect is striking. Q1 results landed on May 11-12, and the immediate market reaction was a 5.3% single-day drop. Within 24 hours, Barclays raised its price target to $20 (from $18) while keeping its Overweight rating. BTIG followed at $18 (from $16), Buy maintained. A week earlier, Citigroup had already moved its target to $24. Every target raise assumes the stock nearly doubles or more from current levels — yet the market is voting in the opposite direction. The consensus stands at Hold with eight analysts on that side, and the mean target is $15.44, a 61% premium to Tuesday's close. The gap between what analysts think the stock is worth and what buyers are willing to pay is as wide as it has been all year.
Short interest adds context to the selling pressure. At 7.1% of free float — up roughly 3.6% on the week — bears have been modestly adding into the post-earnings slide. The month-long trend runs the other way, with SI down 12% over 30 days, suggesting the recent uptick is a tactical addition rather than a structural shift. Cost to borrow is barely noticeable at 0.47% annually, having collapsed from a brief spike above 4% in early April. Borrow availability is extremely loose — the 52-week peak utilization was only 8.86%, and current availability is near the widest end of that range. There is no squeeze dynamic in this name. Bears can add freely and cheaply.
Options positioning tells the most neutral story of all three signals. The put/call ratio is 0.19 — near the middle of its 52-week range (0.11 low, 0.28 high) and only half a standard deviation above its 20-day average. Calls heavily dominate open interest. Options traders are not piling into downside protection; if anything, the market structure still leans bullish even as the stock grinds lower. That combination — cheap borrow, light short positioning, call-skewed options — means the price weakness is being driven by sellers of longs, not an accelerating short campaign.
The bull case rests almost entirely on the pipeline. ARV-102 showed 72% LRRK2 reduction in Parkinson's patients, and the company holds a meaningful ex-US commercialization partnership that validates the platform commercially. Pfizer Venture Investments holds 5.4% of shares, a strategic anchor that has not changed in the latest reported period. The bear argument is more immediate: the LRRK2 space is competitive, with Biogen's BIIB122 as a well-resourced rival, and Arvinas is pre-revenue with a negative P/E. The EV/EBITDA multiple sits at 0.36 — essentially a cash-and-pipeline valuation — reflecting the market's skepticism that the science translates to near-term revenue. Point72 and TCG Crossover both built substantial new positions in Q4 2025, but those reports are now several months stale and predate the current slide.
The most recent insider data runs through mid-March and is therefore not current enough to read as a post-earnings signal. The ORTEX short score holds at 47.5, roughly in the middle of the 0-100 range, consistent with a name that is shorted but not under acute pressure. The next scheduled event is a June 24 readout. Between now and then, the key variable is whether the Rigel Pharmaceuticals licensing agreement for Veppanu — which just closed this week — changes the commercial narrative enough to close the gap between analyst targets and where actual buyers are willing to step in.
See the live data behind this article on ORTEX.
Open ARVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
